Want to see ISCO full AI Analyst Report?
International Stem Cell (ISCO) AI Stock Analysis
International Stem Cell
(Other OTC:ISCO)
ISCO scores near the bottom of the range, driven primarily by its weak financial fundamentals: persistent unprofitability, stagnant revenue, a fragile balance sheet with only $240K in equity, and negligible cash flow. While the significant debt reduction in 2025 and narrowing losses from 2020 levels are positive developments, the company remains far from self-sustaining profitability. The low P/E of 4.56 offers some optical value but is unreliable given earnings quality concerns. Modest technical strength — trading above all moving averages with neutral momentum indicators — provides a small positive offset but is insufficient to overcome the fundamental weaknesses. This is a high-risk micro-cap biotech with limited financial cushion and no clear near-term catalyst for meaningful improvement.
International Stem Cell (ISCO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.12M
- Dividend Yield
- ―
- Average Volume (3M)
- 36.36K
- Price to Earnings (P/E)
- -2.3
- Beta (1Y)
- -0.27
- Revenue Growth
- 3.40%
- EPS Growth
- -101.06%
- Country
- US
- Employees
- 33
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
International Stem Cell Business Overview & Revenue Model
Company Description
International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products...
How the Company Makes Money
ISCO has historically generated revenue through multiple sources tied to its stem cell platforms: (1) sales of stem cell–related products and services (e.g., cell lines, cell-based materials, and/or contract services supporting research and developme...
International Stem Cell Financial Statement Overview
Summary
ISCO's financials are weak across all three statements. Revenue is stagnant at ~$9M with persistent net losses (-$418K in 2025). The balance sheet is extremely fragile with only $240K in equity, and cash flow generation is negligible ($8K operating cash flow). While debt reduction from $3.8M to $393K is a notable positive and losses have narrowed significantly from 2020 levels, the company lacks profitability, meaningful cash generation, and financial flexibility. The income statement score of 32, balance sheet score of 18, and cash flow score of 25 collectively paint a picture of a micro-cap biotech with high financial risk.
Income Statement
32NegativeBalance Sheet
18Very NegativeCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.51M | 9.10M | 9.09M | 7.79M | 8.18M | 7.18M |
| Gross Profit | 5.22M | 5.07M | 5.32M | 4.61M | 4.91M | 4.24M |
| EBITDA | -162.00K | -48.00K | 142.00K | 202.00K | 22.00K | -509.00K |
| Net Income | -582.00K | -418.00K | -209.00K | -131.00K | -466.00K | -1.04M |
Balance Sheet | ||||||
| Total Assets | 5.06M | 4.82M | 5.17M | 5.39M | 5.13M | 4.95M |
| Cash, Cash Equivalents and Short-Term Investments | 1.09M | 993.00K | 1.23M | 1.59M | 742.00K | 171.00K |
| Total Debt | 3.46M | 3.73M | 3.84M | 4.18M | 4.28M | 4.07M |
| Total Liabilities | 4.98M | 8.88M | 9.10M | 5.28M | 9.65M | 9.53M |
| Stockholders Equity | 72.00K | -4.06M | -3.93M | 113.00K | -4.52M | -4.59M |
Cash Flow | ||||||
| Free Cash Flow | 333.00K | -35.00K | -153.00K | 846.00K | 321.00K | -1.34M |
| Operating Cash Flow | 369.00K | 8,000 | 13.00K | 929.00K | 332.00K | -1.30M |
| Investing Cash Flow | -50.00K | -45.00K | -171.00K | -83.00K | -11.00K | -45.00K |
| Financing Cash Flow | -150.00K | -200.00K | -200.00K | 0 | 250.00K | 824.00K |
International Stem Cell Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISCO, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.23, below the 50-day MA of 0.31, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 31.03 is Neutral, neither overbought nor oversold. The STOCH value of 11.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISCO.
International Stem Cell Risk Analysis
International Stem Cell disclosed 55 risk factors in its most recent earnings report. International Stem Cell reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksInternational Stem Cell Peers Comparison
Overall Rating
CELU44Neutral
MBIO43Neutral
LGVN42Neutral
MRKR41Neutral- ISCO40Underperform
BRTX38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CELU | 44Neutral | $25.96M | -0.45 | 142.25% | ― | -58.14% | 47.25% |
| MBIO | 43Neutral | $3.03M | -0.92 | -34.23% | ― | ― | 85.52% |
| LGVN | 42Neutral | $5.32M | -0.17 | -223.19% | ― | -42.74% | 20.66% |
| MRKR | 41Neutral | $16.34M | -1.88 | -56.96% | ― | -56.64% | 64.88% |
| ISCO | 40Underperform | $1.13M | -2.31 | 19.43% | ― | 3.40% | -101.06% |
| BRTX | 38Underperform | $1.93M | -0.07 | -423.84% | ― | -8.47% | 25.62% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ISCO | International Stem Cell Corp | 0.14 | -0.01 | -6.00% | |
| MRKR | Marker Therapeutics | 0.90 | -0.00 | -0.11% | |
| MBIO | Mustang Bio | 0.41 | -0.85 | -67.32% | |
| BRTX | Biorestorative Therapies, Inc. | 1.48 | -27.72 | -94.93% | |
| CELU | Celularity Inc. | 0.80 | -0.92 | -53.37% | |
| LGVN | Longeveron Inc. | 1.71 | -6.29 | -78.63% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Mar 31, 2026